How Undocumented Exceptions Undermine Conversion Programs
The adalimumab biosimilar conversion gap isn't primarily driven by prescribers who have legitimate clinical objections — it's driven by exceptions granted without documentation that could justify them. Manual exception review at scale means requests get approved on volume pressure rather than clinical criteria, and the downstream effect is a formulary tier that payers and plan sponsors paid to enforce that isn't actually being enforced. At $1M–$4M in program cost, a 25-percentage-point shortfall against target represents a significant formulary strategy loss.
Applying Clinical Criteria Consistently Across Every Request
An AI Labor Company agent extracts your exception management logic from Magellan Rx exception histories and Surescripts prescribing pattern data. For every incoming exception request, the agent validates the clinical criteria automatically: requests meeting criteria route to formulary VP approval; requests that don't meet criteria trigger a structured documentation prompt to the prescriber, specifying what clinical justification is required. Conversion rates are tracked by prescriber in Komodo Health and surfaced in Tableau dashboards, giving your team visibility into which practices are driving exception volume. Programs using this structure typically reach the 68%+ conversion threshold, and the agent is live within about six weeks.
The Business Case: Formulary Capture as a Revenue Driver
Biosimilar conversion is a direct cost-of-goods story for a PBM managing $5B–$30B in pharmacy spend. Moving from 45% to 68% conversion on a high-volume specialty molecule like adalimumab translates into measurable rebate capture improvements and net cost reductions that flow directly to plan sponsor satisfaction and contract renewals. Equally important: the audit trail the agent generates — documented clinical justification for every exception, prescriber-level conversion tracking — satisfies CMS and state step therapy law requirements that manual programs struggle to evidence during audit.
How does the agent handle prescribers who repeatedly submit incomplete exception requests?
The agent tracks exception request patterns by prescriber and can escalate repeat incomplete submissions to a formulary management review queue. This creates an intervention opportunity before those prescribers become a systemic drag on conversion rates.
Does the agent integrate with Surescripts for real-time prescribing data?
The agent reads Surescripts prescribing data to contextualize exception requests against established prescribing patterns, helping distinguish genuine clinical preference from volume-driven exception submission behavior.
How does the agent stay current with state step therapy law variations?
State exception criteria are maintained as configurable rule sets within the agent's validation logic. When state regulations change, the relevant rule set is updated without modifying the broader workflow.